BioSpace News Archive

Cytovia Therapeutics, Inc., and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), announced today that they have expanded their collaboration of TALEN® gene-edited iPSC-derived NK and CAR-NK cells to include new CAR target and development in China by Cytovia’s joint venture entity, CytoLynx Therapeutics.

Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers, presented preclinical data from its mucosal healing program in inflammatory bowel disease (IBD) at the Crohn’s & Colitis Foundation’s IBD Innovate: Product Development in Crohn’s & Colitis® virtual conference held November 18-19.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced an update regarding the Phase 2 IMAGINE-DR clinical trial (MK-8507-13), which is evaluating the investigational combination of MK-8507, a non-nucleoside reverse transcriptase inhibitor, and islatravir (ISL), a nucleoside reverse transcriptase translocation inhibitor, as a once-weekly oral treatment for HIV-1 infection.

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), today announced that the China National Medical Products Administration (NMPA) has approved a single-arm dose-finding Phase I/II study designed to evaluate the safety of selinexor (ATG-010) in combination with the R2 regimen of lenalidomide plus rituximab.